Galactose metabolism and health

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 18, Issue 4, 2015, Pages 422-427

  Coelho, Ana I ^a   Berry, Gerard T ^b   Rubio Gozalbo, M Estela ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Energy; Galactose; Glycosylation; Metabolism

Indexed keywords

GALACTOKINASE; GALACTOSE; GALACTOSE 1 PHOSPHATE URIDYLYLTRANSFERASE; URIDINE DIPHOSPHATE GLUCOSE; URIDINE DIPHOSPHATE SUGAR;

ENZYME ACTIVITY; ENZYME REGULATION; GALACTOSEMIA; GLYCOSYLATION; HEALTH; HUMAN; MACROMOLECULE; METABOLISM; METABOLITE; MILK; NONHUMAN; REVIEW; BLOOD; CARBOHYDRATE METABOLISM; DEFICIENCY; GALACTOSEMIAS;

CARBOHYDRATE METABOLISM; GALACTOSE; GALACTOSEMIAS; HUMANS;

EID: 84942742384     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000189     Document Type: Review

References (34)

1. Bell D, editor. Natural monosaccharides and oligosaccharides: Their structures and occurrence. In Florkin M, editor. Comparative biochemistry: A comprehensive treatise. Vol. 3. Elsevier; 2012. pp. 287-354.
2. Georgi G, Bartke N, Wiens F, Stahl B. Functional glycans and glycoconjugates in human milk. Am J Clin Nutr 2013; 98: 578S-585S.
3. Chichlowski M, German JB, Lebrilla CB, Mills DA. The influence of milk oligosaccharides on microbiota of infants: Opportunities for formulas. Annu Rev Food Sci Technol 2011; 2: 331-351.
4. Urashima T, Messer M, Oftedal O. Comparative biochemistry and evolution of milk oligosaccharides of monotremes, marsupials, and eutherians. In: Evolutionary biology: Genome evolution, speciation, coevolution and origin of life. Switzerland: Springer International Publishing; 2014. pp. 3-33.
5. Mills S, Ross RP, Hill C, et al. Milk intelligence: Mining milk for bioactive substances associated with human health. Int Dairy J 2011; 21: 377-401.
6. Hickey RM. The role of oligosaccharides from human milk and other sources in prevention of pathogen adhesion. Int Dairy J 2012; 22: 141-146.
7. Prado EL, Dewey KG. Nutrition and brain development in early life. Nutr Rev 2014; 72: 267-284.
8. Wright EM. Glucose transport families SLC5 and SLC50. Mol Aspects Med 2013; 34: 183-196.
9. Bisha I, Rodriguez A, Laio A, Magistrato A. Metadynamics simulations reveal a Na+ independent exiting path of galactose for the inward-facing conformation of vSGLT. PLoS Comput Biol 2014; 10: E1004017.
10. Augustin R. The protein family of glucose transport facilitators: It's not only about glucose after all. IUBMB Life 2010; 62: 315-333.
11. Leturque A, Brot-Laroche E, Le Gall M. GLUT2 mutations, translocation, and receptor function in diet sugar managing. Am J Physiol Endocrinol Metab 2009; 296: E985-E992.
12. Roser M, Josic D, Kontou M, et al. Metabolism of galactose in the brain and liver of rats and its conversion into glutamate and other amino acids. J Neural Transm 2009; 116: 131-139.
13. Sørensen M. Determination of hepatic galactose elimination capacity using 2-[18F] fluoro-2-deoxy-D-galactose PET/CT: Reproducibility of the method and metabolic heterogeneity in a normal pig liver model. Scand J Gastroenterol 2011; 46: 98-103.
14. Lange A, Grønbæk H, Vilstrup H, Keiding S. Age-dependency of galactose elimination capacity in healthy children and children with chronic liver disease. Scand J Gastroenterol 2011; 46: 197-200.
15. Fridovich-Keil JL, Walter JH. Galactosemia. In: Valle D, Beaudet AL, Vogelstein B, et al., editors. The online metabolic and molecular bases of inherited disease. New York: McGraw Hill; 2008. pp. 1-92.
16. Tang M, Wierenga K, Elsas LJ, Lai K. Molecular and biochemical characterization of human galactokinase and its small molecule inhibitors. Chem Biol Interact 2010; 188: 376-385.
17. Chiappori F, Merelli I, Milanesi L, Marabotti A. Static and dynamic interactions between GALK enzyme and known inhibitors: Guidelines to design new drugs for galactosemic patients. Eur J Med Chem 2013; 63: 423-434.
18. McCorvie TJ, Timson DJ. The structural and molecular biology of type I galactosemia: Enzymology of galactose 1-phosphate uridylyltransferase. IUBMB Life 2011; 63: 694-700.
19. McCorvie TJ, Timson DJ. UDP-galactose-4-epimerase (GALE). In Taniguchi N, Honke K, Fukuda M, et al., editors. Handbook of glycosyltransferases and related genes. Japan: Springer; 2014. pp. 1449-1464.
20. Décombaz J,JentjensR, IthM,etal.Fructoseandgalactoseenhancepostexercise human liver glycogen synthesis. Med Sci Sports Exerc 2011; 43: 1964-1971.
21. Berry GT, Walter JH. Disorders of galactose metabolism. In Saudubray JM, van den Berghe G, Walter JH, editors. Inborn metabolic diseases: Diagnosis and treatment. Germany: Springer; 2012.
22. Varki A, Esko JD, Colley KJ. Cellular organization of glycosylation. In: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of glycobiology. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 2009.
23. Hadley B,MaggioniA,AshikovA, et al.Structure and function of nucleotide sugar transporters: Current progress. Comput Struct Biotechnol J 2014; 10: 23-32.
24. Cummings R, Pierce J. The challenge and promise of glycomics. Chem Biol 2014; 21: 1-15.
25. Berry GT. Is prenatal myo-inositol deficiency a mechanism of CNS injury in galactosemia? J Inherit Metab Dis 2011; 34: 345-355.
26. Waisbren SE, Potter NL, Gordon CM, et al. The adult galactosemic phenotype. J Inherit Metab Dis 2012; 35: 279-286.
27. Coss KP, Hawkes CP, Adamczyk B, et al. N-glycan abnormalities in children with galactosemia. J Proteome Res 2014; 13: 385-394.
28. Coss KP, Treacy EP, Cotter EJ, et al. Systemic gene dysregulation in classical galactosaemia: Is there a central mechanism? Mol Genet Metab 2014; 113: 177-187.
29. Coss KP, Byrne JC, Coman DJ, et al. IgG N-glycans as potential biomarkers for determining galactose tolerance in Classical Galactosaemia. Mol Genet Metab 2012; 105: 212-220.
30. Coelho AI, Trabuco M, Ramos R, et al. Functional and structural impact of the most prevalent missense mutations in classic galactosemia. Mol Genet Genom Med 2014; 2: 484-496.
31. McCorvie TJ, Gleason TJ, Fridovich-Keil JL, Timson DJ. Misfolding of galactose 1-phosphate uridylyltransferase can result in type I galactosemia. Biochim Biophys Acta 2013; 1832: 1279-1293.
32. Berry GT, Elsas LJ. Introduction to the Maastricht workshop: Lessons from the past and new directions in galactosemia. J Inherit Metab Dis 2011; 34: 249-255.
33. Salkovic-Petrisic M, Osmanovic-Barilar J, Knezovic A, et al. Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin. Neuropharmacology 2014; 77: 68-80.
34. Tegtmeyer L, Rust S, van Scherpenzeel M, et al. Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med 2014; 370: 533-542.